Pfizer targets genomics through Pfizergen

摘要

ALEENTOWN, Penn --Late last year. Rhone-PouJenc Rorer (RPR, Collegevilie, PA) took an innovative step in putting together RPR-Genceli, a 14- member gene ther apy aad cell therapy consortium .dedicated to developing and commer-cializing these therapies. "It's cleat that a variety of technologies--a tool box, if you will--is requited to engineer development in this area," says Robert Cawthorn, RPR's chairman and chief executive officer. "Our answer is an integrated network of external and internal scientists that will share the tools and expertise necessary to build successful cell therapeutics and gene therapeutics on an accelerated timeline." Though initial payments to the consortium totaled just 15 million dollar, RPR-Gencell's operating budget this year is expected to reach about 100 million dollar.